RLAY
Relay Therapeutics
$18.64
+$0.20 (+1.08%)Jul 27, 2026
Key metrics
The numbers that frame RLAY today
- Market cap
- $3.57B
- P/E (TTM)
- -13.1
- EV / FCF
- -15.9
- Gross margin
- 100%
- EV / Sales
- 318.1
- ROIC
- -48.9%
- Div yield
- 0%
- Debt / equity
- 0.0
- 52wk Low
- $3.03
- 52wk High
- $20.79
Growth
Revenue and earnings trend for RLAY
RevenueNet income
See the full growth breakdown
Revenue and earnings trends, margins and the multi-year trajectory - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inCash flow & returns
Free cash flow and financial health
Free cash flowNet debt
See the full cash-flow picture
Free cash flow detail, returns on capital and the balance-sheet trend - free with an account.
Create a free accountFree foreverNo card required
Already a member? Log inInsider trading
Recent insider buying and selling activity
PurchasesSales
Unlock every insider trade
See who is buying and selling, how much, and when - updated as new filings land.
Create a free accountFree foreverNo card required
Already a member? Log inFrequently asked questions
Plain-English answers about RLAY
Is Relay Therapeutics a good buy?
Hold. Relay Therapeutics has excellent momentum, but poor quality makes the setup mixed. Growth looks poor. That could put pressure on the long-term business case. We think Relay Therapeutics is selling at a very high price.
What is the market capitalization of RLAY?
Relay Therapeutics's market capitalization is $3.57B.
What is the P/E ratio for RLAY stock?
Relay Therapeutics's current P/E ratio is -13.1.
What is the 52-week high for RLAY stock?
The 52-week high for Relay Therapeutics is $20.79. The current close of $18.64 is 10.3% below that high.
What is the 52-week low for RLAY stock?
The 52-week low for Relay Therapeutics is $3.03. The current close of $18.64 is 516.2% above that low.
Does RLAY stock pay dividends?
Relay Therapeutics does not currently show a dividend per share in the company data.
What is the Debt / Equity ratio for RLAY?
Relay Therapeutics's Debt / Equity ratio is 0.05.